Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Merck’s Antiviral Drug Meets Primary Endpoint in Phase III Clinical Trial

XTALKS VITALS NEWS

In addition, patients in the Phase III clinical trial who were given the antiviral prophylactically, showed a lower mortality rate after the procedure.

Share this!

February 28, 2017 | by Sarah Hand, M.Sc.

Merck’s investigational antiviral medicine, letermovir, has met its primary endpoint of reducing the incidence of cytomegalovirus (CMV) infection in adults following a bone marrow transplant. In addition, patients in the Phase III clinical trial who were given the antiviral prophylactically, showed a lower mortality rate after the procedure.

“These results showed that letermovir prophylaxis beginning after hematopoietic stem cell transplant (HSCT) and continuing through Day 100 post-transplant significantly reduced CMV infection requiring preemptive antiviral therapy through Week 24 post-transplant,” said Dr. Francisco M. Marty, associate professor of medicine at Harvard Medical School and attending physician in transplant and oncology infectious diseases at Dana-Farber Cancer Institute and Brigham and Women’s Hospital. “In this study, letermovir was associated with lower all-cause mortality. Based on these findings, letermovir as primary prophylaxis of CMV infection represents a potential new strategy for the prevention of CMV in this high-risk patient population.”

This latest data was presented on Sunday at the BMT Tandem Meetings – the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT). According to Merck, they intend to apply for approval of letermovir in the US and the EU this year.



CMV is a common virus which is normally asymptomatic in healthy individuals. However, when a patient is immunosuppressed – as is the case for patients following a bone marrow transplant as treatment for hematological cancers – CMV can cause serious complications, including organ damage and failure.

All patients in the Phase III clinical trial had previously been exposed to CMV, but were not suffering from an active infection at the time of the study. While generic antiviral drugs are available to reduce the risk of infection following an HSCT, they are largely underused due to issues of safety and efficacy.

The results of the study showed that 37.5 percent of patients treated with letermovir developed a CMV infection by the 24-week post-HSCT mark, compared to 60.6 percent for the placebo. Letermovir was also associated with lower all-cause mortality, with 9.8 percent of patients given the antiviral dying before week 24, compared to 15.9 percent for the placebo.

“There is an unmet need for therapeutic options in the prevention of CMV infection in hematopoietic stem cell transplant recipients,” said Dr. Nicholas Kartsonis, vice president, infectious disease clinical research, Merck Research Laboratories. “As part of Merck’s long-standing commitment to developing innovative approaches in the fight against infectious diseases, we look forward to submitting regulatory applications for letermovir this year.”

According to FierceBiotech, Credit Suisse analysts have predicted that letermovir could see sales of $370 million by the year 2020, if approved by regulators. Despite its potential, letermovir shows no activity against other viruses, making it vulnerable to competition from more broad-spectrum antivirals, like Chimerix' brincidofovir.


Keywords: Antiviral, Clinical Trial, Bone Marrow Transplant


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.